News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MEIP under $5
|
Followers
|
80
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1396
|
|
Created
|
11/05/12
|
Type
|
Free
|
| Moderators | |||
MEI Pharma (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our portfolio of drug candidates includes Pracinostat, an oral HDAC inhibitor being developed in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Our clinical development pipeline also includes ME-401, a highly selective oral PI3K delta inhibitor, and ME-344, a novel mitochondrial inhibitor.
http://www.meipharma.com/our-programs/pracinostat
In August 2016, we announced that the U.S. Food & Drug Administration granted Breakthrough Therapy Designation for Pracinostat in combination with azacitidine for the treatment of patients with newly diagnosed AML who are ≥75 years of age or unfit for intensive chemotherapy. Later that month, we entered into an exclusive licensing, development and commercialization agreement with Helsinn Healthcare, SA, a Swiss pharmaceutical corporation, for Pracinostat in AML and other potential indications, including MDS.
http://www.meipharma.com/our-programs/me-401
ME-401 is a potent and selective oral inhibitor of PI3K delta, a molecular target that plays a critical role in the proliferation and survival of certain hematologic cancer cells. Results from a first-in-human, single ascending dose clinical study suggest that ME-401 has the potential for an improved therapeutic window compared to other PI3K delta inhibitors, with a half-life that supports once-daily dosing. A Phase Ib dose-escalation study of ME-401 in patients with recurrent chronic lymphocytic leukemia (CLL) or follicular non-Hodgkin's lymphoma (fNHL) opened for enrollment in September 2016.
http://www.meipharma.com/our-programs/me-344
ME-344 is our isoflavone-derived mitochondrial inhibitor drug candidate. Results from a Phase I clinical study of ME-344 in patients with refractory solid tumors showed evidence of clinical activity, including a confirmed partial response in a heavily pre-treated patient with small cell lung cancer who remained on study for two years. An investigator-sponsored study of ME-344 in combination with the VEGF inhibitor bevacizumab (marketed as Avastin®) in HER2-negative breast cancer opened for enrollment in August 2016.
MEI Pharma is listed on the Nasdaq Capital Market (Nasdaq: MEIP).
Financial Highlights as of September 30, 2016
- $58.9 million in cash
- No debt
- 36.8 million shares outstanding
Company website:
http://www.meipharma.com
Company presentation:
http://www.meipharma.com/sites/default/files/meip_presentation_-_stifel_nov_2016_-_final_2_0.pdf
